Menarini partners on clinical stage oncology drug SEL24

Italian family-controlled drug maker Menarini, through its subsidiary Berlin-Chemie Menarini, has entered into a global license agreement for SEL24, a dual PIM/FLT3 inhibitor currently in Phase I/II trials in acute myeloid leukemia (AML) patients, with Poland’s Selvita (WSE: SLV).

SEL24 is a Selvita-developed first-in-class orally available dual PIM/FLT3 kinase inhibitor with a unique activity profile. While it is currently investigated for the treatment of patients with relapsed/refractory (R/R) AML, preclinical data suggest potential activity in other hematological malignancies and solid tumors. The program entered Phase I/II in early 2017.

"We are excited to sign a license agreement for SEL24 with the Menarini Group," said Pawel Prewiezlikowski, chief executive at Selvita, adding: "This collaboration takes us another step closer to delivering a much-needed new treatment for AML patients. Menarini Group dedication to providing transformative therapies for people courageously facing various life-threatening diseases such as cancer, assures us that the potential of SEL24 in treatment of cancer patients will be fully realized."